Therapy of Type 2 diabetes: more gliflozines and less metformin?

Metformin is a frequently used anti-diabetic drug. In addition to the well-known modulating properties on glyco-metabolic control, metformin reduces cardiovascular (CV) risk partly independently of its anti-hyperglycaemic effect. The use of ‘new’ anti-diabetic drugs, inhibitors of the renal Na-gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdecchia, Paolo, Murdolo, Giuseppe, Coiro, Stefano, Santucci, Andrea, Notaristefano, Francesco, Angeli, Fabio, Cavallini, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
CCC 2023 - State of the Art Cardiology Supplement Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120941/
https://www.ncbi.nlm.nih.gov/pubmed/37091638
http://dx.doi.org/10.1093/eurheartjsupp/suad098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120941/
https://www.ncbi.nlm.nih.gov/pubmed/37091638
http://dx.doi.org/10.1093/eurheartjsupp/suad098

Ejemplares similares